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ABSTRACT
The ability of breakpoint and serum concentra-
tions of teicoplanin, vancomycin, linezolid and
quinupristin–dalfopristin to select resistance was
compared for isolates of methicillin-susceptible
Staphylococcus aureus (MSSA), methicillin-resistant
S. aureus (MRSA), Enterococcus faecalis and Entero-
coccus faecium. Mutation frequencies were always
<10)10, except for two isolates grown in the
presence of teicoplanin at the trough serum
concentration. After multistep selection, linezolid
selected for resistance in staphylococci and entero-
cocci, and serial exposure to certain concentrations
of linezolid was more likely to select for stable
resistance in MRSA, MSSA and enterococci than
was exposure to glycopeptides and quinupristin–
dalfopristin.
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For many years, glycopeptides were considered to
be the cornerstone of therapy for serious methi-
cillin-resistant staphylococcal infections [1].
However, the spread of vancomycin-resistant
enterococci is now a concern in hospitals world-
wide, with vancomycin-resistant enterococci hav-
ing become established nosocomial pathogens
[2,3]. Following the first report of failure of
vancomycin therapy because of a vancomycin-
intermediate-resistant Staphylococcus aureus strain
in 1997 [4], an increasing number of isolates with
decreased susceptibility to glycopeptides has
been identified worldwide [5,6]. Moreover,
shortly after the introduction of linezolid and
quinupristin–dalfopristin, both of which were
designed specifically to treat infections caused
by Gram-positive bacteria, occasional resistance
to both drugs has been reported in clinical isolates
of Gram-positive cocci [7–9]. The present study
investigated the ability of teicoplanin (Sanofi-
Aventis, Milan, Italy), vancomycin (Sigma-
Aldrich, St Louis, MO, USA), linezolid (Pfizer,
Rome, Italy) and quinupristin–dalfopristin (Sano-
fi-Aventis) to select for resistance in 20 clinical
isolates each of methicillin-resistant S. aureus
(MRSA), methicillin-susceptible S. aureus, Entero-
coccus faecalis and Enterococcus faecium.
Drugs were evaluated at the following concen-
trations, equal to the resistance breakpoint (BP)
and the peak and minimum serum concentrations
(Cmax and Cmin, respectively): teicoplanin
32 mg ⁄L (BP), 43.2 mg ⁄L (Cmax), 10 mg ⁄L (Cmin);
vancomycin 32 mg ⁄L (BP), 66 mg ⁄L (Cmax),
8 mg ⁄L (Cmin); quinupristin–dalfopristin 4 mg ⁄L
(BP), 9.50 mg ⁄L (Cmax); and linezolid 8 mg ⁄L
(BP), 15.7 mg ⁄L (Cmax), 3.84 mg ⁄L (Cmin) [10–14].
No data concerning Cmin were available for
quinupristin–dalfopristin. The frequency of muta-
tion (number of colonies growing on plates
containing antibiotic divided by the total inocu-
lum) was determined by spreading 0.1 mL from a
bacterial suspension containing c. 1011 CFU ⁄mL
on plates containing each antibiotic at BP, Cmax
and Cmin [15]. MICs for colonies grown on
antibiotic-containing plates were determined by
microdilution according to CLSI recommenda-
tions [10].
Selection for resistance was evaluated by seri-
ally subculturing bacteria on agar plates contain-
ing linear antibiotic concentrations ranging from
0 mg ⁄L to the BP, Cmax and Cmin [16]. An
inoculum of 1011 CFU ⁄mL was spread homoge-
neously on each plate and incubated for 48 h at
37C. Colonies growing at the highest antibiotic
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concentration were sampled, grown overnight in
antibiotic-free broth, re-inoculated ten times on
new antibiotic gradient plates, and then ten times
on antibiotic-free plates to evaluate the stability of
acquired resistance. MIC values were determined
after the first, the fifth and the final passage on
antibiotic-containing agar, and after the first, the
fifth and the final passage on antibiotic-free agar.
The potential for antibiotics to promote
increased rates of mutation has clear implications
for the evolution of antibiotic resistance among
bacterial pathogens [17]. Although antimicrobial
therapy aims to target an infecting organism with
lethal or inhibitory concentrations, antibiotic con-
centrations often fall below the inhibitory level
in vivo, or may fail to reach an inhibitory level in
some body compartments. For this reason, selec-
tion of resistance was evaluated at concentrations
commonly achieved during therapy. Frequencies
of mutation were low for all the antibiotics tested
(<10)10); only two MRSA isolates were able to
grow on plates containing teicoplanin at the
trough concentration, so that the frequency of
mutation ranged from 1.7 · 10)8 to <10)10. How-
ever, despite growth, the MICs for these two
selected isolates (1 mg ⁄L) did not exceed the
resistance breakpoint for teicoplanin.
The use of antibiotic gradients in the multistep
selection assay allowed the impact of a wide range
of concentrations on resistance development to be
explored. The study revealed that Cmax did not
select for resistance in staphylococci andE. faecium,
even if increases in MICs of teicoplanin and
quinupristin–dalfopristin were revealed (Tables 1
and 2). In contrast, high concentrations of linezolid
were unable to prevent selection of resistance in
E. faecalis, while no changes in susceptibility were
observed for glycopeptides (Table 2).
Differences in favour of glycopeptides and
quinupristin–dalfopristin with respect to linezolid
were also observed with BP or Cmin concentra-
tions. Although all the antibiotics selected for an
incremental increase in MICs, only the mutants
selected by linezolid were stably resistant
(Tables 1 and 2). Differences in stability of resis-
tance between glycopeptides and linezolid could
be caused by a different degree of fitness in
resistant mutants. Indeed, the fitness burden,
associated with alterations in cell-wall morphol-
ogy, is thought to account for the widely observed
instability of the resistant phenotype [18].
In 2006, vancomycin breakpoints for S. aureus
were changed (from £4 to £2 mg ⁄mL for ‘suscep-
tible’, from 8–16 to 4–8 mg ⁄mL for ‘intermediate’,
Table 1. MIC values for Staphylococcus aureus before and after serial passage on antibiotic-gradient agar plates and on
antibiotic-free plates
Drug Concentrationa
MIC range (mg/L)/no. resistant mutants
Baseline One step Five steps Ten steps Ten steps freeb
MRSA
Teicoplanin BP (32 mg ⁄L)
Cmax (43.2 mg ⁄L)
Cmin (10 mg ⁄L)
0.125–2
0.125–2
0.125–2
0.25–8 ⁄ 0
0.5–4 ⁄ 0
1–8 ⁄ 0
0.5–8 ⁄ 0
2–8 ⁄ 0
1–8 ⁄ 0
8–32 ⁄ 3
8–16 ⁄ 0
4–32 ⁄ 7
1–16 ⁄ 0
2–16 ⁄ 0
1–16 ⁄ 0
Vancomycin BP (32 mg ⁄L)
Cmax (66 mg ⁄L)
Cmin (8 mg ⁄L)
0.5–1
0.5–1
0.5–1
0.5–2 ⁄ 0
0.5–1 ⁄ 0
0.5–2 ⁄ 0
0.5–4 ⁄ 0
0.5–1 ⁄ 0
0.5–4 ⁄ 0
0.5–32 ⁄ 1
0.5–1 ⁄ 0
2–32 ⁄ 4
0.5–8 ⁄ 0
0.5–1 ⁄ 0
1–8 ⁄ 0
Linezolid BP (8 mg ⁄L)
Cmax (15.7 mg ⁄L)
Cmin (3.84 mg ⁄L)
1–2
1–2
1–2
1–4 ⁄ 0
1–2 ⁄ 0
1–4 ⁄ 0
1–64 ⁄ 4
1–2 ⁄ 0
1–8 ⁄ 2
2–64 ⁄ 6
1–2 ⁄ 0
2–8 ⁄ 5
2–32 ⁄ 6
1–2 ⁄ 0
2–8 ⁄ 3
Quinupristin–dalfopristin BP (4 mg ⁄L)
Cmax (9.5 mg ⁄L)
0.125–0.5
0.125–0.5
0.25–1 ⁄ 0
0.125–0.5 ⁄ 0
0.25–1 ⁄ 0
0.5–1 ⁄ 0
1–2 ⁄ 0
0.5–4 ⁄ 0
0.25–1 ⁄ 0
0.25–4 ⁄ 0
MSSA
Teicoplanin BP (32 mg ⁄L)
Cmax (43.2 mg ⁄L)
Cmin (10 mg ⁄L)
0.125–0.5
0.125–0.5
0.125–0.5
0.125–2 ⁄ 0
0.25–2 ⁄ 0
0.5–8 ⁄ 0
0.125–8 ⁄ 0
0.25–8 ⁄ 0
2–16 ⁄ 0
0.125–16 ⁄ 0
0.25–16 ⁄ 0
2–16 ⁄ 0
0.125–4 ⁄ 0
0.25–8 ⁄ 0
1–8 ⁄ 0
Vancomycin BP (32 mg ⁄L)
Cmax (66 mg ⁄L)
Cmin (8 mg ⁄L)
0.125–0.5
0.125–0.5
0.125–0.5
0.125–0.5 ⁄ 0
0.125–0.5 ⁄ 0
0.125–1 ⁄ 0
0.125–2 ⁄ 0
0.125–0.5 ⁄ 0
1–4 ⁄ 0
0.125–4 ⁄ 0
0.125–0.5 ⁄ 0
1–4 ⁄ 0
0.125–1 ⁄ 0
0.125–0.5 ⁄ 0
0.125–1 ⁄ 0
Linezolid BP (8 mg ⁄L)
Cmax (15.7 mg ⁄L)
Cmin (3.84 mg ⁄L)
0.5–2
0.5–2
0.5–2
2–4 ⁄ 0
0.5–2 ⁄ 0
2–4 ⁄ 0
4–8 ⁄ 4
0.5–2 ⁄ 0
2–16 ⁄ 6
4–32 ⁄ 6
1–2 ⁄ 0
4–32 ⁄ 9
4–16 ⁄ 4
0.5–2 ⁄ 0
4–32 ⁄ 4
Quinupristin–dalfopristin BP (4 mg ⁄L)
Cmax (9.5 mg ⁄L)
0.06–0.5
0.06–0.5
0.125–0.5 ⁄ 0
0.06–0.5 ⁄ 0
0.25–0.5 ⁄ 0
0.06–0.5 ⁄ 0
0.125–0.5 ⁄ 0
0.06–0.5 ⁄ 0
0.125–0.5 ⁄ 0
0.06–0.5 ⁄ 0
MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; BP, resistance breakpoint; Cmax, peak serum concentration; Cmin, trough serum concentration.
aValues indicate the highest concentrations in the gradient plates.
bSubcultures on antibiotic-free agar.
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and from ‡32 to ‡16 mg ⁄mL for ‘resistant’) to
enhance the detection of heterogeneously resis-
tant isolates of S. aureus [19]. According to the
new interpretative criteria, four and six MRSA
isolates should be reclassified as resistant at the
BP and Cmin concentrations, respectively.
A limitation of the present study was that total
concentrations of antimicrobial agents were
assessed, without any consideration of protein-
binding. Since protein-binding varies widely
among the agents tested, it might affect the results
obtained, particularly for teicoplanin, which is
associated with high serum protein-binding.
However, the high level of protein-binding may
act as an ‘antibiotic reservoir’ that reversibly
releases antibiotics from the binding sites as
serum and tissue concentrations decrease, pro-
vided that serum concentrations are sufficiently
high to guarantee effective levels in the blood [20].
In conclusion, these in-vitro studies with con-
centrations of glycopeptides, quinupristin–dalfo-
pristin and linezolid achievable in vivo suggest
that optimal antimicrobial peak concentrations
are able to prevent, or at least to limit, the
occurrence of resistance. Selecting dosing regi-
mens on the basis of pharmacokinetic and phar-
macodynamic properties is of utmost importance
in preventing the emergence of resistance. Expo-
sure in vitro to certain concentrations of linezolid
seems more likely to select for stable resistance
among isolates of MRSA, methicillin-susceptible
S. aureus and enterococci than is exposure to gly-
copeptides and quinupristin–dalfopristin. Care
should be taken to use appropriate prescribing of
these new agents for the treatment of patients with
infections caused by Gram-positive bacteria.
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ABSTRACT
Rapid detection and typing of methicillin-resis-
tant Staphylococcus aureus are important compo-
nents of infection control programmes. A protocol
is described that enables sequencing of the spa
gene fragment directly from a multiplex PCR
targeting the clinically relevant mecA, pvl and spa
genes, resulting in high-throughput characterisa-
tion of S. aureus. Implementation of the method in
the Danish national reference laboratory has
markedly reduced the use of reagents and the
requirement for hands-on time, and has also
provided fast typing results. In addition, the
method reduces the risk of sample mishandling.
Keywords Detection, direct sequencing, MRSA, mul-
tiplex PCR, spa typing, typing
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The emergence and spread of strains of meth-
icillin-resistant Staphylococcus aureus (MRSA) is
a major healthcare concern in many parts of the
world. MRSA surveillance should include, as a
minimum, detection of the mecA gene and
typing of the isolates, and detection of the pvl
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